ABSTRACT Introduction Alpha1-blockers (AB) are the first-line monotherapy for lower
urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors are the first-line …

Background Phosphodiesterase type 5 inhibitors and α-adrenergic blocking agents (α-
blockers) are widely used for the treatment of erectile dysfunction (ED) and lower urinary …

OBJECTIVES: This pilot study was undertaken to assess the efficacy and safety of the α1-
blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the …

Alpha1‐adrenergic blockers (α1‐blockers) are considered the most effective monotherapy
for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia …

CONTEXT: A large body of epidemiologic data suggests a causal relationship between
lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). Recently reported …

OBJECTIVES: To examine the hemodynamic interactions of the phosphodiesterase type 5
(PDE-5) inhibitor tadalafil with the uroselective alpha1-blocker alfuzosin (10 mg daily) …

Context The effects of combination therapy consisted of an α-blocker and a
phosphodiesterase-5 inhibitor (PDE5I) for the treatment of lower urinary tract symptoms …

OBJECTIVE To provide an update on the efficacy and safety of tadalafil, a
phosphodiesterase‐5 inhibitor, in the treatment of erectile dysfunction (ED). PATIENTS AND …

As the prevalence of both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS)
increases with age, physicians could be in the position to manage these two conditions …

Associate Editor Michael G. Wyllie Editorial Board Ian Eardley, UK Jean Fourcroy, USA
Sidney Glina, Brazil Julia Heiman, USA Chris McMahon, Australia Bob Millar, UK Alvaro …